BioXcel Therapeutics, Inc. short interest in 2020
In 2020, BioXcel Therapeutics, Inc.'s disclosed short interest ran from 2.53% of shares outstanding on 15 Jan 2020 to 13.66% on 31 Dec 2020, a change of +11.13 percentage points. The year's high was 13.92% on 31 Jul 2020 and its low 2.34% on 14 Feb 2020, averaging 7.92% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.17 days on 30 Nov 2020. Full history: BioXcel Therapeutics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2020 in figures
- Start of year
- 2.53% (15 Jan 2020)
- End of year
- 13.66% (31 Dec 2020)
- Change
- +11.13 pp
- High
- 13.92% (31 Jul 2020)
- Low
- 2.34% (14 Feb 2020)
- Average
- 7.92%
- Highest days to cover
- 9.17 (30 Nov 2020)
Every report in 2020
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2020 | 2.53% | 1.00 | |
| 31 Jan 2020 | 2.45% | 2.17 | |
| 14 Feb 2020 | 2.34% | 1.00 | |
| 28 Feb 2020 | 2.70% | 1.00 | |
| 13 Mar 2020 | 3.80% | 1.03 | |
| 31 Mar 2020 | 3.00% | 1.21 | |
| 15 Apr 2020 | 3.25% | 1.81 | |
| 30 Apr 2020 | 4.22% | 1.89 | |
| 15 May 2020 | 3.87% | 1.88 | |
| 29 May 2020 | 3.34% | 1.96 | |
| 15 Jun 2020 | 4.68% | 2.96 | |
| 30 Jun 2020 | 11.09% | 3.91 | |
| 15 Jul 2020 | 10.69% | 5.96 | |
| 31 Jul 2020 | 13.92% | 2.70 | |
| 14 Aug 2020 | 10.79% | 4.43 | |
| 31 Aug 2020 | 9.64% | 3.65 | |
| 15 Sep 2020 | 10.30% | 4.77 | |
| 30 Sep 2020 | 12.04% | 5.76 | |
| 15 Oct 2020 | 10.40% | 4.99 | |
| 30 Oct 2020 | 12.65% | 6.30 | |
| 13 Nov 2020 | 12.11% | 7.63 | |
| 30 Nov 2020 | 13.41% | 9.17 | |
| 15 Dec 2020 | 13.09% | 8.81 | |
| 31 Dec 2020 | 13.66% | 7.78 |
See also: BioXcel Therapeutics, Inc.'s full history · most shorted US stocks of 2020 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.